IQPC to hold the 8th Annual Polymorphism & Crystallization Scientific Forum

Organized by IQPC, the 8th Annual Polymorphism & Crystallization Scientific Forum will be held October 26-28, 2009 at the Hub Cira Center in Philadelphia, PA.

Reducing costs through accelerated drug development pipelines and the adoption of new analytical methods continues to be a major focus for bio-pharmaceutical organizations. The 8th Polymorphism & Crystallization Scientific Forum provides novel best practices from leading pharmaceutical and academic experts to better understand and rationalize co-crystal discovery and selection.

Leaders from Wyeth, Pfizer, AstraZeneca, Hoffman La Roche, GlaxoSmithKline, Eli Lilly & Company and the Center for Pharmaceutical Physics will present case studies on improving solubility and increasing bioavailability of polymorphs and salts, including:

• Practical uses of amorphous API’s
• Improvement of solid state chemical stability through form selection and physical stability of salts of weak bases
• Salt and polymorph selection strategies based on the Biopharmaceutical Classification System (BCS) for early development
• Modulation of solubility and dissolution rates of crystalline substances and the effects of identity and particle size
• The role of XRPD in accelerating phase identification and selection

In addition, the forum provides the opportunity for brainstorm with peers during in-depth roundtable discussions on identification and quantitation of forms, developing integrated approaches to solid state development, chiral co-crystals, and patent strategies for co-crystals.